These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19305697)

  • 1. Income-based drug coverage in British Columbia: the impact on access to medicines.
    Caetano PA; Raymond CB; Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e154-69. PubMed ID: 19305697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Income-based drug coverage in British Columbia: the impact on private and public expenditures.
    Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e129-53. PubMed ID: 19305696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.
    Morgan S; Evans RG; Hanley GE; Caetano PA; Black C
    Healthc Policy; 2006 Nov; 2(2):115-27. PubMed ID: 19305708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Income-based drug coverage in british columbia: towards an understanding of the policy.
    Morgan S; Coombes M
    Healthc Policy; 2006 Nov; 2(2):92-108. PubMed ID: 19305707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.
    Hanley GE; Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e170-86. PubMed ID: 19305698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Barer M; Reid RJ
    Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
    Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
    CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using policy simulation to predict drug plan expenditure when planning reimbursement changes.
    Dormuth CR; Burnett S; Schneeweiss S
    Pharmacoeconomics; 2005; 23(10):1021-30. PubMed ID: 16235975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of medication reviews by community pharmacists.
    Kolhatkar A; Cheng L; Chan FK; Harrison M; Law MR
    J Am Pharm Assoc (2003); 2016; 56(5):513-520.e1. PubMed ID: 27594104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of allowing pharmacists to independently renew prescriptions: A population-based study.
    Law MR; Cheng L; Kratzer J; Morgan SG; Marra C; Lynd LD; Majumdar SR
    J Am Pharm Assoc (2003); 2015; 55(4):398-404. PubMed ID: 26115380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.
    Wang PS; Patrick AR; Dormuth C; Maclure M; Avorn J; Canning CF; Schneeweiss S
    J Ment Health Policy Econ; 2010 Mar; 13(1):37-44. PubMed ID: 20571181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
    Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription duration after drug copay changes in older people: methodological aspects.
    Schneeweiss S; Maclure M; Soumerai SB
    J Am Geriatr Soc; 2002 Mar; 50(3):521-5. PubMed ID: 11943050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with hypertension treatment among community-dwelling BC seniors.
    Morgan SG; Yan L
    Can J Clin Pharmacol; 2004; 11(2):e267-73. PubMed ID: 15596883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns, predictors and persistence of chronic sedative use: a population-based observational study of older adults in British Columbia, Canada.
    Morgan SG; Weymann D
    Eur J Clin Pharmacol; 2017 Aug; 73(8):1001-1008. PubMed ID: 28435984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of restrictive prescription plans on heart failure medication use.
    Thanassoulis G; Karp I; Humphries K; Tu JV; Eisenberg MJ; Pilote L
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):484-90. PubMed ID: 20031881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
    Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
    Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study.
    Morgan SG; Gladstone EJ; Weymann D; Khan N
    CMAJ Open; 2017; 5(1):E198-E204. PubMed ID: 28401135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based analysis of statin utilization in British Columbia.
    Raymond CB; Morgan SG; Katz A; Kozyrskyj AL
    Clin Ther; 2007 Sep; 29(9):2107-19. PubMed ID: 18035209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.